WHAT IS CLAIMED IS:

1. Use of benralizumab or an antigen-binding fragment thereof in the manufacture of a medicament for reducing the annual exacerbation rate of asthma, wherein a fixed dose of the medicament comprising 30 mg of benralizumab is to be administered to an asthma patient once every four weeks for twelve weeks then once every eight weeks, wherein the administration reduces the patient's exacerbation rate.

2. Use of benralizumab or an antigen-binding fragment thereof in the manufacture of a medicament for the treatment of asthma, wherein a fixed dose of the medicament comprising 30 mg of benralizumab is to be administered to an asthma patient once every four weeks for twelve weeks then once every eight weeks, wherein the patient has a blood eosinophil count of at least 300 cells/µl prior to the administration.

3. Use of benralizumab or an antigen-binding fragment thereof in the manufacture of a medicament for the treatment of asthma, wherein a fixed dose of the medicament comprising 30 mg of benralizumab is to be administered to an asthma patient once every four weeks for twelve weeks then once every eight weeks, wherein the patient has a forced expiratory volume in one second (FEV_1) of at least 40% and less than 90% predicted value prior to the administration.

4. Use of benralizumab or an antigen-binding fragment thereof in the manufacture of a medicament for the treatment of asthma, wherein a fixed dose of the medicament comprising 30 mg of benralizumab is to be administered to an asthma patient once every four weeks for twelve weeks then once every eight weeks, wherein the patient has a forced expiratory volume in one second (FEV_1) of below 75% predicted value prior to the administration.

5. The use of any one of claims 2-4, wherein the administration reduces the patient's exacerbation rate.

6. The use of claim 5, wherein the administration reduces the patient's annual exacerbation rate.

7. The use of any one of claims 1 or 3-6, wherein the asthma is eosinophilic asthma.

8. The use of any one of claims 1 or 3-7, wherein the patient has a blood eosinophil count of at least 300 cells/µl.

9. The use of any one of claims 1-2, wherein, the patient has a forced expiratory volume in one second (FEV_1) of at least 75% predicted value prior to the administration.

10. The use of any one of claims 1-9, wherein at least two doses of the medicament are to be administered to the patient.

11. The use of any one of claims 1 or 6-10, which reduces the annual exacerbations rate following administration of the medicament.

12. The use of any one of claims 1 or 6-11, wherein the annual exacerbation rate is reduced by at least 35%.

13. The use of claim 12, wherein the annual exacerbation rate is reduced by at least 40%.

14. The use of claim 13, wherein the annual exacerbation rate is reduced by at least 50%.

15. The use of claim 14, wherein the annual exacerbation rate is reduced by at least 60%.

16. The use of any one of claims 1-15, wherein the patient uses high-dose inhaled corticosteroids (ICS).

17. The use of any one of claims 1-16, wherein the patient uses long-acting β2 agonists (LABA).

18. The use of any one of claims 1-17, wherein the patient has a history of exacerbations.

19. The use of claim 18, wherein the history of exacerbations comprises at least two exacerbations in the year prior to the administration of the medicament.

20. The use of claim 18 or 19, wherein the history of exacerbations comprises no more than six exacerbations in the year prior to the administration of the medicament.